Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases
Aim We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series. Methods Ki67 proliferation index, microvascular density (MVD) and hypoxia‐inducible factor 1 alpha (HIF‐1 alpha) index were determined by immunohis...
Saved in:
Published in | Neuropathology and applied neurobiology Vol. 41; no. 2; pp. e41 - e55 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Blackwell Publishing Ltd
01.02.2015
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aim
We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series.
Methods
Ki67 proliferation index, microvascular density (MVD) and hypoxia‐inducible factor 1 alpha (HIF‐1 alpha) index were determined by immunohistochemistry in BM and primary tumour specimens.
Results
Six hundred thirty‐nine BM specimens of 639 patients with lung cancer (344/639; 53.8%), breast cancer (105/639; 16.4%), melanoma (67/639; 10.5%), renal cell carcinoma (RCC; 52/639; 8.1%) or colorectal cancer (CRC; 71/639; 11.1%) were available. Specimens of the corresponding primary tumour were available in 113/639 (17.7%) cases. Median Ki67 index was highest in CRC BM and lowest in RCC BM (P < 0.001). MVD and HIF‐1 alpha index were both highest in RCC BM and lowest in melanoma BM (P < 0.001). Significantly higher Ki67 indices, MVD and HIF‐1 alpha indices in the BM than in matched primary tumours were observed for breast cancer, non‐small cell lung cancer (NSCLC) and CRC. Correlation of tissue‐based parameters with overall survival in individual tumour types showed a favourable and independent prognostic impact of low Ki67 index [hazard ratio (HR) 1.015; P < 0.001] in NSCLC BM and of low Ki67 index (HR 1.027; P = 0.008) and high angiogenic activity (HR 1.877; P = 0.002) in RCC.
Conclusion
Our data argue for differential pathobiological and clinical relevance of Ki67 index, HIF1‐alpha index and MVD between primary tumour types in BM patients. An independent prognostic impact of tissue‐based characteristics was observed in patients with BM from NSCLC and RCC, supporting the incorporation of these tissue‐based parameters into diagnosis‐specific prognostic scores. |
---|---|
AbstractList | Aim
We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series.
Methods
Ki67 proliferation index, microvascular density (MVD) and hypoxia‐inducible factor 1 alpha (HIF‐1 alpha) index were determined by immunohistochemistry in BM and primary tumour specimens.
Results
Six hundred thirty‐nine BM specimens of 639 patients with lung cancer (344/639; 53.8%), breast cancer (105/639; 16.4%), melanoma (67/639; 10.5%), renal cell carcinoma (RCC; 52/639; 8.1%) or colorectal cancer (CRC; 71/639; 11.1%) were available. Specimens of the corresponding primary tumour were available in 113/639 (17.7%) cases. Median Ki67 index was highest in CRC BM and lowest in RCC BM (P < 0.001). MVD and HIF‐1 alpha index were both highest in RCC BM and lowest in melanoma BM (P < 0.001). Significantly higher Ki67 indices, MVD and HIF‐1 alpha indices in the BM than in matched primary tumours were observed for breast cancer, non‐small cell lung cancer (NSCLC) and CRC. Correlation of tissue‐based parameters with overall survival in individual tumour types showed a favourable and independent prognostic impact of low Ki67 index [hazard ratio (HR) 1.015; P < 0.001] in NSCLC BM and of low Ki67 index (HR 1.027; P = 0.008) and high angiogenic activity (HR 1.877; P = 0.002) in RCC.
Conclusion
Our data argue for differential pathobiological and clinical relevance of Ki67 index, HIF1‐alpha index and MVD between primary tumour types in BM patients. An independent prognostic impact of tissue‐based characteristics was observed in patients with BM from NSCLC and RCC, supporting the incorporation of these tissue‐based parameters into diagnosis‐specific prognostic scores. AIMWe aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series.METHODSKi67 proliferation index, microvascular density (MVD) and hypoxia-inducible factor 1 alpha (HIF-1 alpha) index were determined by immunohistochemistry in BM and primary tumour specimens.RESULTSSix hundred thirty-nine BM specimens of 639 patients with lung cancer (344/639; 53.8%), breast cancer (105/639; 16.4%), melanoma (67/639; 10.5%), renal cell carcinoma (RCC; 52/639; 8.1%) or colorectal cancer (CRC; 71/639; 11.1%) were available. Specimens of the corresponding primary tumour were available in 113/639 (17.7%) cases. Median Ki67 index was highest in CRC BM and lowest in RCC BM (P < 0.001). MVD and HIF-1 alpha index were both highest in RCC BM and lowest in melanoma BM (P < 0.001). Significantly higher Ki67 indices, MVD and HIF-1 alpha indices in the BM than in matched primary tumours were observed for breast cancer, non-small cell lung cancer (NSCLC) and CRC. Correlation of tissue-based parameters with overall survival in individual tumour types showed a favourable and independent prognostic impact of low Ki67 index [hazard ratio (HR) 1.015; P < 0.001] in NSCLC BM and of low Ki67 index (HR 1.027; P = 0.008) and high angiogenic activity (HR 1.877; P = 0.002) in RCC.CONCLUSIONOur data argue for differential pathobiological and clinical relevance of Ki67 index, HIF1-alpha index and MVD between primary tumour types in BM patients. An independent prognostic impact of tissue-based characteristics was observed in patients with BM from NSCLC and RCC, supporting the incorporation of these tissue-based parameters into diagnosis-specific prognostic scores. Aim We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis ( BM ) series. Methods K i67 proliferation index, microvascular density ( MVD ) and hypoxia‐inducible factor 1 alpha ( HIF ‐1 alpha) index were determined by immunohistochemistry in BM and primary tumour specimens. Results Six hundred thirty‐nine BM specimens of 639 patients with lung cancer (344/639; 53.8%), breast cancer (105/639; 16.4%), melanoma (67/639; 10.5%), renal cell carcinoma ( RCC ; 52/639; 8.1%) or colorectal cancer ( CRC ; 71/639; 11.1%) were available. Specimens of the corresponding primary tumour were available in 113/639 (17.7%) cases. Median K i67 index was highest in CRC BM and lowest in RCC BM ( P < 0.001). MVD and HIF ‐1 alpha index were both highest in RCC BM and lowest in melanoma BM ( P < 0.001). Significantly higher K i67 indices, MVD and HIF ‐1 alpha indices in the BM than in matched primary tumours were observed for breast cancer, non‐small cell lung cancer ( NSCLC ) and CRC . Correlation of tissue‐based parameters with overall survival in individual tumour types showed a favourable and independent prognostic impact of low K i67 index [hazard ratio ( HR ) 1.015; P < 0.001] in NSCLC BM and of low K i67 index ( HR 1.027; P = 0.008) and high angiogenic activity ( HR 1.877; P = 0.002) in RCC . Conclusion Our data argue for differential pathobiological and clinical relevance of K i67 index, HIF 1‐alpha index and MVD between primary tumour types in BM patients. An independent prognostic impact of tissue‐based characteristics was observed in patients with BM from NSCLC and RCC , supporting the incorporation of these tissue‐based parameters into diagnosis‐specific prognostic scores. We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series. Ki67 proliferation index, microvascular density (MVD) and hypoxia-inducible factor 1 alpha (HIF-1 alpha) index were determined by immunohistochemistry in BM and primary tumour specimens. Six hundred thirty-nine BM specimens of 639 patients with lung cancer (344/639; 53.8%), breast cancer (105/639; 16.4%), melanoma (67/639; 10.5%), renal cell carcinoma (RCC; 52/639; 8.1%) or colorectal cancer (CRC; 71/639; 11.1%) were available. Specimens of the corresponding primary tumour were available in 113/639 (17.7%) cases. Median Ki67 index was highest in CRC BM and lowest in RCC BM (P < 0.001). MVD and HIF-1 alpha index were both highest in RCC BM and lowest in melanoma BM (P < 0.001). Significantly higher Ki67 indices, MVD and HIF-1 alpha indices in the BM than in matched primary tumours were observed for breast cancer, non-small cell lung cancer (NSCLC) and CRC. Correlation of tissue-based parameters with overall survival in individual tumour types showed a favourable and independent prognostic impact of low Ki67 index [hazard ratio (HR) 1.015; P < 0.001] in NSCLC BM and of low Ki67 index (HR 1.027; P = 0.008) and high angiogenic activity (HR 1.877; P = 0.002) in RCC. Our data argue for differential pathobiological and clinical relevance of Ki67 index, HIF1-alpha index and MVD between primary tumour types in BM patients. An independent prognostic impact of tissue-based characteristics was observed in patients with BM from NSCLC and RCC, supporting the incorporation of these tissue-based parameters into diagnosis-specific prognostic scores. Aim We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series. Methods Ki67 proliferation index, microvascular density (MVD) and hypoxia-inducible factor 1 alpha (HIF-1 alpha) index were determined by immunohistochemistry in BM and primary tumour specimens. Results Six hundred thirty-nine BM specimens of 639 patients with lung cancer (344/639; 53.8%), breast cancer (105/639; 16.4%), melanoma (67/639; 10.5%), renal cell carcinoma (RCC; 52/639; 8.1%) or colorectal cancer (CRC; 71/639; 11.1%) were available. Specimens of the corresponding primary tumour were available in 113/639 (17.7%) cases. Median Ki67 index was highest in CRC BM and lowest in RCC BM (P<0.001). MVD and HIF-1 alpha index were both highest in RCC BM and lowest in melanoma BM (P<0.001). Significantly higher Ki67 indices, MVD and HIF-1 alpha indices in the BM than in matched primary tumours were observed for breast cancer, non-small cell lung cancer (NSCLC) and CRC. Correlation of tissue-based parameters with overall survival in individual tumour types showed a favourable and independent prognostic impact of low Ki67 index [hazard ratio (HR) 1.015; P<0.001] in NSCLC BM and of low Ki67 index (HR 1.027; P=0.008) and high angiogenic activity (HR 1.877; P=0.002) in RCC. Conclusion Our data argue for differential pathobiological and clinical relevance of Ki67 index, HIF1-alpha index and MVD between primary tumour types in BM patients. An independent prognostic impact of tissue-based characteristics was observed in patients with BM from NSCLC and RCC, supporting the incorporation of these tissue-based parameters into diagnosis-specific prognostic scores. |
Author | Zielinski, Christoph C. Hainfellner, Johannes A. Widhalm, Georg Hackl, Monika Dinhof, Carina Berghoff, Anna S. Dieckmann, Karin Bartsch, Rupert Ilhan-Mutlu, Aysegül Magerle, Manuel Melchardt, Thomas Birner, Peter Pichler, Josef Preusser, Matthias Hutterer, Markus |
Author_xml | – sequence: 1 givenname: Anna S. surname: Berghoff fullname: Berghoff, Anna S. organization: Institute of Neurology, Medical University of Vienna, Vienna, Austria – sequence: 2 givenname: Aysegül surname: Ilhan-Mutlu fullname: Ilhan-Mutlu, Aysegül organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria – sequence: 3 givenname: Carina surname: Dinhof fullname: Dinhof, Carina organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria – sequence: 4 givenname: Manuel surname: Magerle fullname: Magerle, Manuel organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria – sequence: 5 givenname: Monika surname: Hackl fullname: Hackl, Monika organization: Austrian National Cancer Registry, Statistics Austria, ViennaVienna, Austria – sequence: 6 givenname: Georg surname: Widhalm fullname: Widhalm, Georg organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria – sequence: 7 givenname: Johannes A. surname: Hainfellner fullname: Hainfellner, Johannes A. organization: Institute of Neurology, Medical University of Vienna, Vienna, Austria – sequence: 8 givenname: Karin surname: Dieckmann fullname: Dieckmann, Karin organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria – sequence: 9 givenname: Josef surname: Pichler fullname: Pichler, Josef organization: Department of Medicine and Neurooncology, Landes-Nervenklinik Wagner-Jauregg, Linz, Austria – sequence: 10 givenname: Markus surname: Hutterer fullname: Hutterer, Markus organization: Department of Neurology, Christian-Doppler-Klinik, Paracelsus Medical University, Salzburg, Austria – sequence: 11 givenname: Thomas surname: Melchardt fullname: Melchardt, Thomas organization: 3rd Medical Department, Paracelsus Medical University Hospital Salzburg, Salzburg, Austria – sequence: 12 givenname: Rupert surname: Bartsch fullname: Bartsch, Rupert organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria – sequence: 13 givenname: Christoph C. surname: Zielinski fullname: Zielinski, Christoph C. organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria – sequence: 14 givenname: Peter surname: Birner fullname: Birner, Peter organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria – sequence: 15 givenname: Matthias surname: Preusser fullname: Preusser, Matthias email: matthias.preusser@meduniwien.ac.at organization: Comprehensive Cancer Center CNS Tumors Unit, Medical University of Vienna, Vienna, Austria |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25256708$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kd9qFDEYxYO02G31wheQgDd6MW3-TDKJd3Vra6GsRRTFm5CZ-bKkziR1MoPuM_jSzbi7vRAMISHwO-fL4RyjgxADIPSCklOa11mw4ZQyqsQTtKBcioJpTQ7QgnAiCqpKeYSOU7ojhIhK6qfoiAkmZEXUAv258M7BAGH0tsND7ABHh21Y-7iGAMmn_GjxOPVxGnADXYfvM-Wzxo4-BuwDrgebzx5Gm_KGrGiaOLQ-rPEYM-57O2z2FuPmHt5mT9ttZvM8THKNm1n3DB062yV4vrtP0JfL95-XH4qbj1fXy_ObouGaigIUISAlaOCa1K4C20iiWq0db5ksAVQtW2dbRoTg1EnZAFOlq4WtXNXqlp-g11vfnOTnBGk0vU9zNBsgTslQKVjJSq51Rl_9g97lEPnzM1UqVRFCZ-rNlmqGmNIAzuxCG0rM3JDJDZm_DWX25c5xqntoH8l9JRk42wK_fAeb_zuZ1flqb1lsFT6N8PtRYYcfRla8Eubr6srcfrtY0u-378wn_gDBtK2d |
CODEN | NANEDL |
CitedBy_id | crossref_primary_10_1186_s13550_023_01052_8 crossref_primary_10_1111_his_12709 crossref_primary_10_1093_annonc_mdw532 crossref_primary_10_1158_1078_0432_CCR_18_1624 crossref_primary_10_1158_0008_5472_CAN_19_3560 crossref_primary_10_1016_j_clineuro_2019_03_016 crossref_primary_10_1093_jnen_nlz007 crossref_primary_10_1007_s11060_016_2235_5 crossref_primary_10_1634_theoncologist_2016_0117 crossref_primary_10_1038_s41588_019_0423_x crossref_primary_10_1093_neuonc_noac131 crossref_primary_10_1007_s12254_018_0384_2 crossref_primary_10_18632_oncotarget_11488 crossref_primary_10_3390_ijms24043854 crossref_primary_10_1007_s10143_016_0760_5 crossref_primary_10_1007_s10585_016_9832_8 crossref_primary_10_1016_j_clcc_2015_05_009 crossref_primary_10_3390_cancers13040603 crossref_primary_10_1186_s12894_017_0306_3 crossref_primary_10_21294_1814_4861_2020_19_1_119_125 crossref_primary_10_18632_oncotarget_4201 crossref_primary_10_1158_0008_5472_CAN_20_2251 crossref_primary_10_18632_oncotarget_5696 crossref_primary_10_1016_j_critrevonc_2018_08_001 crossref_primary_10_3390_ijms23136934 crossref_primary_10_1016_S0007_4551_18_30381_3 crossref_primary_10_1007_s13277_015_3790_7 crossref_primary_10_1186_s13058_021_01480_1 crossref_primary_10_1002_nbm_4948 crossref_primary_10_1111_1759_7714_12818 crossref_primary_10_1038_s41598_021_90662_0 crossref_primary_10_1093_noajnl_vdaa038 crossref_primary_10_1007_s10585_020_10055_x crossref_primary_10_1007_s11060_020_03513_9 crossref_primary_10_3389_fonc_2021_670313 crossref_primary_10_1038_s41568_020_00300_6 crossref_primary_10_2217_bmm_2017_0161 crossref_primary_10_1016_j_clineuro_2021_106537 crossref_primary_10_1136_esmoopen_2015_000024 crossref_primary_10_3389_fonc_2021_714514 crossref_primary_10_3390_cancers16122242 |
Cites_doi | 10.1007/s10585-012-9552-7 10.1016/j.cell.2011.02.013 10.1586/era.10.165 10.1016/j.ijrobp.2007.06.074 10.1227/NEU.0000000000000354 10.1007/BF00666038 10.1016/S0895-4356(00)00314-0 10.3109/07357907.2010.535059 10.1007/s11060-013-1194-3 10.1007/s10585-014-9675-0 10.1007/s00066-014-0639-8 10.1111/bju.12263 10.1016/j.clineuro.2013.06.019 10.1016/j.lungcan.2010.08.005 10.1111/j.1750-3639.2003.tb00013.x 10.1016/j.radonc.2011.08.041 10.1016/j.semcancer.2012.06.001 10.1158/1078-0432.CCR-04-1776 10.1158/1078-0432.CCR-09-2439 10.1002/jcb.22214 10.1371/journal.pone.0092311 10.1093/annonc/mdp411 10.1016/j.ejca.2010.11.033 10.3171/2012.2.JNS111353 10.1093/neuonc/not112 10.1016/j.ejca.2012.07.002 10.1007/s11060-009-0061-8 10.1016/j.lungcan.2005.03.036 10.1007/s11060-009-9938-9 10.1038/bjc.2014.71 10.1371/journal.pone.0005857 10.1038/labinvest.2011.153 10.1586/14737140.2013.852067 10.5414/NP300600 10.1111/j.1468-1331.2006.01506.x 10.1038/nm.2072 10.3171/2013.9.JNS13788 10.1111/j.1365-2559.2008.03065.x |
ContentType | Journal Article |
Copyright | 2014 British Neuropathological Society 2014 British Neuropathological Society. Copyright © 2015 British Neuropathological Society |
Copyright_xml | – notice: 2014 British Neuropathological Society – notice: 2014 British Neuropathological Society. – notice: Copyright © 2015 British Neuropathological Society |
DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TK K9. 7X8 |
DOI | 10.1111/nan.12185 |
DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1365-2990 |
EndPage | e55 |
ExternalDocumentID | 3572294611 10_1111_nan_12185 25256708 NAN12185 ark_67375_WNG_PXDC1ZPB_R |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Medical University of Vienna funderid: H‐263727/2013 |
GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 123 1OB 1OC 29N 31~ 33P 36B 3SF 3UE 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAVGM AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABHUG ABJNI ABPTK ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXME ACXQS ADAWD ADBBV ADBTR ADDAD ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFVGU AFZJQ AGJLS AHBTC AHEFC AHMBA AIACR AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EAD EAP EAS EBC EBD EBS EBX EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA GSXLS H.X HF~ HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YFH ZA5 ZGI ZXP ZZTAW ~IA ~WT AITYG HGLYW OIG CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TK K9. 7X8 |
ID | FETCH-LOGICAL-c3915-e800e66e9e390bf7eac608d99f3d264ee8b6dfad205531f66ce284fb5a7f7d9d3 |
IEDL.DBID | DR2 |
ISSN | 0305-1846 |
IngestDate | Fri Aug 16 01:33:27 EDT 2024 Fri Sep 13 07:35:29 EDT 2024 Fri Aug 23 00:57:04 EDT 2024 Sat Sep 28 08:12:40 EDT 2024 Sat Aug 24 00:58:49 EDT 2024 Wed Jan 17 05:01:26 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | ki67 proliferation index microvascular density HIF-1 alpha index brain metastases |
Language | English |
License | 2014 British Neuropathological Society. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3915-e800e66e9e390bf7eac608d99f3d264ee8b6dfad205531f66ce284fb5a7f7d9d3 |
Notes | ark:/67375/WNG-PXDC1ZPB-R ArticleID:NAN12185 Medical University of Vienna - No. H-263727/2013 istex:8B7C749114817DC06F17E09B3B636C3516898B0F ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 25256708 |
PQID | 1648870019 |
PQPubID | 1096364 |
PageCount | 15 |
ParticipantIDs | proquest_miscellaneous_1652424399 proquest_journals_1648870019 crossref_primary_10_1111_nan_12185 pubmed_primary_25256708 wiley_primary_10_1111_nan_12185_NAN12185 istex_primary_ark_67375_WNG_PXDC1ZPB_R |
PublicationCentury | 2000 |
PublicationDate | 2015-02 February 2015 2015-Feb 2015-02-00 20150201 |
PublicationDateYYYYMMDD | 2015-02-01 |
PublicationDate_xml | – month: 02 year: 2015 text: 2015-02 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Oxford |
PublicationTitle | Neuropathology and applied neurobiology |
PublicationTitleAlternate | Neuropathol Appl Neurobiol |
PublicationYear | 2015 |
Publisher | Blackwell Publishing Ltd Wiley Subscription Services, Inc |
Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley Subscription Services, Inc |
References | Bachtiary B, Schindl M, Potter R, Dreier B, Knocke TH, Hainfellner JA, Horvat R, Birner P. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 2003; 9: 2234-2240 Preusser M, Heinzl H, Gelpi E, Hoftberger R, Fischer I, Pipp I, Milenkovic I, Wohrer A, Popovici F, Wolfsberger S, Hainfellner JA. Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology 2008; 53: 39-47 Park S, Ha SY, Cho HY, Chung DH, Kim NR, Hong J, Cho EK. Prognostic implications of hypoxia-inducible factor-1alpha in epidermal growth factor receptor-negative non-small cell lung cancer. Lung Cancer 2011; 72: 100-107 Berghoff AS, Preusser M. Biology in prevention and treatment of brain metastases. Expert Rev Anticancer Ther 2013; 13: 1339-1348 Kienast Y, Winkler F. Therapy and prophylaxis of brain metastases. Expert Rev Anticancer Ther 2010; 10: 1763-1777 Kim SJ, Rabbani ZN, Dewhirst MW, Vujaskovic Z, Vollmer RT, Schreiber EG, Oosterwijk E, Kelley MJ. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 2005; 49: 325-335 Shen C, Kaelin WG Jr. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 2013; 23: 18-25 Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008; 70: 510-514 Scoccianti S, Ricardi U. Treatment of brain metastases: review of phase III randomized controlled trials. Radiother Oncol 2012; 102: 168-179 Berghoff AS, Ilhan-Mutlu A, Wohrer A, Hackl M, Widhalm G, Hainfellner JA, Dieckmann K, Melchardt T, Dome B, Heinzl H, Birner P, Preusser M. Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases. Strahlenther Onkol 2014; 190: 676-685 Gayed BA, Youssef RF, Bagrodia A, Darwish OM, Kapur P, Sagalowsky A, Lotan Y, Margulis V. Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma. BJU Int 2014; 113: 668-673 Jenkinson MD, Haylock B, Shenoy A, Husband D, Javadpour M. Management of cerebral metastasis: evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy. Eur J Cancer 2011; 47: 649-655 Rades D, Dziggel L, Segedin B, Oblak I, Nagy V, Marita A, Schild SE. The first survival score for patients with brain metastases from small cell lung cancer (SCLC). Clin Neurol Neurosurg 2013; 115: 2029-2032 Harter PN, Zinke J, Scholz A, Tichy J, Zachskorn C, Kvasnicka HM, Goeppert B, Delloye-Bourgeois C, Hattingen E, Senft C, Steinbach JP, Plate KH, Mehlen P, Schulte D, Mittelbronn M. Netrin-1 expression is an independent prognostic factor for poor patient survival in brain metastases. PLoS ONE 2014; 9: e92311 Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010; 16: 269-278 Carbonell WS, Ansorge O, Sibson N, Muschel R. The vascular basement membrane as 'soil' in brain metastasis. PLoS ONE 2009; 4: e5857 Preusser M, Winkler F, Collette L, Haller S, Marreaud S, Soffietti R, Klein M, Reijneveld JC, Tonn JC, Baumert BG, Mulvenna P, Schadendorf D, Duchnowska R, Berghoff AS, Lin N, Cameron DA, Belkacemi Y, Jassem J, Weber DC. Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. Eur J Cancer 2012; 48: 3439-3447 Kondziolka D, Kalkanis SN, Mehta MP, Ahluwalia M, Loeffler JS. It is time to reevaluate the management of patients with brain metastases. Neurosurgery 2014; 75: 1-9 Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ambros PF, Ambros IM, Bredel M, Oberhuber G, Rossler K, Budka H, Harris AL, Hainfellner JA. Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol 2003; 13: 133-143 Saroufim A, Messai Y, Hasmim M, Rioux N, Iacovelli R, Verhoest G, Bensalah K, Patard JJ, Albiges L, Azzarone B, Escudier B, Chouaib S. Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma. Br J Cancer 2014; 110: 1778-1784 Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF, Williams GH. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 2005; 11: 2510-2517 Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, Cobbs CS, Ammirati M, Robinson PD, Andrews DW, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell RA, Ryken TC, Linskey ME. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96: 33-43 Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5835 Cochran DC, Chan MD, Aklilu M, Lovato JF, Alphonse NK, Bourland JD, Urbanic JJ, McMullen KP, Shaw EG, Tatter SB, Ellis TL. The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg 2012; 116: 978-983 Wohrer A, Waldhor T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mosenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A, Richling B, Idriceanu C, Scarpatetti M, Sedivy R, Bankl HC, Stiglbauer W, Preusser M, Rossler K, Hainfellner JA. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 2009; 95: 401-411 Berghoff AS, Kovanda AK, Melchardt T, Bartsch R, Hainfellner JA, Sipos B, Schittenhelm J, Zielinski CC, Widhalm G, Dieckmann K, Weller M, Goodman SL, Birner P, Preusser M. Alphavbeta3, alphavbeta5 and alphavbeta6 integrins in brain metastases of lung cancer. Clin Exp Metastasis 2014 (in press) Wu PF, Huang WC, Yang JC, Lu YS, Shih JY, Wu SG, Lin CH, Cheng AL. Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas. J Neurooncol 2013; 115: 61-70 Soffietti R, Cornu P, Delattre JY, Grant R, Graus F, Grisold W, Heimans J, Hildebrand J, Hoskin P, Kalljo M, Krauseneck P, Marosi C, Siegal T, Vecht C. EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur J Neurol 2006; 13: 674-681 Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009; 107: 1053-1062 Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, Winkler F. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 2010; 16: 116-122 Woehrer A. Brain tumor epidemiology in Austria and the Austrian Brain Tumor Registry. Clin Neuropathol 2013; 32: 269-285 Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995; 36: 169-180 Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 2010; 21: 1027-1031 Kondziolka D, Parry PV, Lunsford LD, Kano H, Flickinger JC, Rakfal S, Arai Y, Loeffler JS, Rush S, Knisely JP, Sheehan J, Friedman W, Tarhini AA, Francis L, Lieberman F, Ahluwalia MS, Linskey ME, McDermott M, Sperduto P, Stupp R. The accuracy of predicting survival in individual patients with cancer. J Neurosurg 2014; 120: 24-30 Bleckmann A, Siam L, Klemm F, Rietkotter E, Wegner C, Kramer F, Beissbarth T, Binder C, Stadelmann C, Pukrop T. Nuclear LEF1/TCF4 correlate with poor prognosis but not with nuclear beta-catenin in cerebral metastasis of lung adenocarcinomas. Clin Exp Metastasis 2013; 30: 471-482 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674 Berghoff AS, Rajky O, Winkler F, Bartsch R, Furtner J, Hainfellner JA, Goodman SL, Weller M, Schittenhelm J, Preusser M. Invasion patterns in brain metastases of solid cancers. Neuro-Oncol 2013; 15: 1664-1672 Bender R, Lange S. Adjusting for multiple testing-when and how? J Clin Epidemiol 2001; 54: 343-349 Iakovlev VV, Gabril M, Dubinski W, Scorilas A, Youssef YM, Faragalla H, Kovacs K, Rotondo F, Metias S, Arsanious A, Plotkin A, Girgis AH, Streutker CJ, Yousef GM. Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study. Lab Invest 2012; 92: 46-56 Toma MI, Weber T, Meinhardt M, Zastrow S, Grimm MO, Fussel S, Wirth MP, Baretton GB. Expression of the Forkhead transcription factor FOXP1 is associated with tumor grade and Ki67 expression in clear cell renal cell carcinoma. Cancer Invest 2011; 29: 123-129 2010; 10 2010; 16 2012; 102 2006; 13 1995; 36 2013; 23 2014; 190 2003; 13 2008; 53 2014; 110 2005; 49 2008; 70 2014; 113 2010; 21 2012; 92 2013; 15 2009; 95 2013; 32 2013; 13 2013; 115 1999; 59 2003; 9 2011; 72 2013; 30 2014 2011; 47 2009; 4 2012; 48 2013 2014; 9 2009; 107 2012; 116 2011; 29 2014; 120 2010; 96 2005; 11 2011; 144 2001; 54 2014; 75 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 Bachtiary B (e_1_2_8_23_1) 2003; 9 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_21_1 e_1_2_8_42_1 e_1_2_8_22_1 e_1_2_8_41_1 e_1_2_8_40_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_39_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_16_1 e_1_2_8_37_1 Zhong H (e_1_2_8_27_1) 1999; 59 e_1_2_8_32_1 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_30_1 |
References_xml | – volume: 120 start-page: 24 year: 2014 end-page: 30 article-title: The accuracy of predicting survival in individual patients with cancer publication-title: J Neurosurg – volume: 92 start-page: 46 year: 2012 end-page: 56 article-title: Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study publication-title: Lab Invest – volume: 13 start-page: 133 year: 2003 end-page: 143 article-title: Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes publication-title: Brain Pathol – volume: 190 start-page: 676 year: 2014 end-page: 685 article-title: Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non‐small cell lung cancer brain metastases publication-title: Strahlenther Onkol – volume: 53 start-page: 39 year: 2008 end-page: 47 article-title: Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker publication-title: Histopathology – volume: 59 start-page: 5830 year: 1999 end-page: 5835 article-title: Overexpression of hypoxia‐inducible factor 1alpha in common human cancers and their metastases publication-title: Cancer Res – volume: 144 start-page: 646 year: 2011 end-page: 674 article-title: Hallmarks of cancer: the next generation publication-title: Cell – volume: 29 start-page: 123 year: 2011 end-page: 129 article-title: Expression of the Forkhead transcription factor FOXP1 is associated with tumor grade and Ki67 expression in clear cell renal cell carcinoma publication-title: Cancer Invest – volume: 36 start-page: 169 year: 1995 end-page: 180 article-title: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors publication-title: Breast Cancer Res Treat – volume: 13 start-page: 674 year: 2006 end-page: 681 article-title: EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force publication-title: Eur J Neurol – volume: 54 start-page: 343 year: 2001 end-page: 349 article-title: Adjusting for multiple testing–when and how? publication-title: J Clin Epidemiol – volume: 23 start-page: 18 year: 2013 end-page: 25 article-title: The VHL/HIF axis in clear cell renal carcinoma publication-title: Semin Cancer Biol – volume: 10 start-page: 1763 year: 2010 end-page: 1777 article-title: Therapy and prophylaxis of brain metastases publication-title: Expert Rev Anticancer Ther – volume: 47 start-page: 649 year: 2011 end-page: 655 article-title: Management of cerebral metastasis: evidence‐based approach for surgery, stereotactic radiosurgery and radiotherapy publication-title: Eur J Cancer – volume: 48 start-page: 3439 year: 2012 end-page: 3447 article-title: Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012 publication-title: Eur J Cancer – volume: 75 start-page: 1 year: 2014 end-page: 9 article-title: It is time to reevaluate the management of patients with brain metastases publication-title: Neurosurgery – volume: 15 start-page: 1664 year: 2013 end-page: 1672 article-title: Invasion patterns in brain metastases of solid cancers publication-title: Neuro‐Oncol – volume: 107 start-page: 1053 year: 2009 end-page: 1062 article-title: Role of hypoxia in the hallmarks of human cancer publication-title: J Cell Biochem – volume: 9 start-page: 2234 year: 2003 end-page: 2240 article-title: Overexpression of hypoxia‐inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer publication-title: Clin Cancer Res – volume: 21 start-page: 1027 year: 2010 end-page: 1031 article-title: Incidence of brain metastases in renal cell carcinoma treated with sorafenib publication-title: Ann Oncol – volume: 96 start-page: 33 year: 2010 end-page: 43 article-title: The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence‐based clinical practice guideline publication-title: J Neurooncol – volume: 4 start-page: e5857 year: 2009 article-title: The vascular basement membrane as ‘soil’ in brain metastasis publication-title: PLoS ONE – volume: 16 start-page: 269 year: 2010 end-page: 278 article-title: Bevacizumab safety in patients with central nervous system metastases publication-title: Clin Cancer Res – volume: 9 start-page: e92311 year: 2014 article-title: Netrin‐1 expression is an independent prognostic factor for poor patient survival in brain metastases publication-title: PLoS ONE – volume: 16 start-page: 116 year: 2010 end-page: 122 article-title: Real‐time imaging reveals the single steps of brain metastasis formation publication-title: Nat Med – year: 2014 article-title: Alphavbeta3, alphavbeta5 and alphavbeta6 integrins in brain metastases of lung cancer publication-title: Clin Exp Metastasis – volume: 110 start-page: 1778 year: 2014 end-page: 1784 article-title: Tumoral CD105 is a novel independent prognostic marker for prognosis in clear‐cell renal cell carcinoma publication-title: Br J Cancer – volume: 115 start-page: 2029 year: 2013 end-page: 2032 article-title: The first survival score for patients with brain metastases from small cell lung cancer (SCLC) publication-title: Clin Neurol Neurosurg – volume: 113 start-page: 668 year: 2014 end-page: 673 article-title: Ki67 is an independent predictor of oncological outcomes in patients with localized clear‐cell renal cell carcinoma publication-title: BJU Int – volume: 11 start-page: 2510 year: 2005 end-page: 2517 article-title: Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma publication-title: Clin Cancer Res – volume: 49 start-page: 325 year: 2005 end-page: 335 article-title: Expression of HIF‐1alpha, CA IX, VEGF, and MMP‐9 in surgically resected non‐small cell lung cancer publication-title: Lung Cancer – volume: 95 start-page: 401 year: 2009 end-page: 411 article-title: The Austrian Brain Tumour Registry: a cooperative way to establish a population‐based brain tumour registry publication-title: J Neurooncol – volume: 32 start-page: 269 year: 2013 end-page: 285 article-title: Brain tumor epidemiology in Austria and the Austrian Brain Tumor Registry publication-title: Clin Neuropathol – volume: 70 start-page: 510 year: 2008 end-page: 514 article-title: A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database publication-title: Int J Radiat Oncol Biol Phys – volume: 116 start-page: 978 year: 2012 end-page: 983 article-title: The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery publication-title: J Neurosurg – volume: 72 start-page: 100 year: 2011 end-page: 107 article-title: Prognostic implications of hypoxia‐inducible factor‐1alpha in epidermal growth factor receptor‐negative non‐small cell lung cancer publication-title: Lung Cancer – volume: 30 start-page: 471 year: 2013 end-page: 482 article-title: Nuclear LEF1/TCF4 correlate with poor prognosis but not with nuclear beta‐catenin in cerebral metastasis of lung adenocarcinomas publication-title: Clin Exp Metastasis – volume: 115 start-page: 61 year: 2013 end-page: 70 article-title: Phosphorylated insulin‐like growth factor‐1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas publication-title: J Neurooncol – volume: 13 start-page: 1339 year: 2013 end-page: 1348 article-title: Biology in prevention and treatment of brain metastases publication-title: Expert Rev Anticancer Ther – volume: 102 start-page: 168 year: 2012 end-page: 179 article-title: Treatment of brain metastases: review of phase III randomized controlled trials publication-title: Radiother Oncol – year: 2013 – ident: e_1_2_8_37_1 doi: 10.1007/s10585-012-9552-7 – ident: e_1_2_8_7_1 doi: 10.1016/j.cell.2011.02.013 – ident: e_1_2_8_4_1 doi: 10.1586/era.10.165 – ident: e_1_2_8_13_1 doi: 10.1016/j.ijrobp.2007.06.074 – ident: e_1_2_8_21_1 doi: 10.1227/NEU.0000000000000354 – ident: e_1_2_8_18_1 doi: 10.1007/BF00666038 – ident: e_1_2_8_19_1 doi: 10.1016/S0895-4356(00)00314-0 – ident: e_1_2_8_32_1 doi: 10.3109/07357907.2010.535059 – ident: e_1_2_8_40_1 doi: 10.1007/s11060-013-1194-3 – ident: e_1_2_8_41_1 doi: 10.1007/s10585-014-9675-0 – ident: e_1_2_8_15_1 doi: 10.1007/s00066-014-0639-8 – volume: 9 start-page: 2234 year: 2003 ident: e_1_2_8_23_1 article-title: Overexpression of hypoxia‐inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer publication-title: Clin Cancer Res contributor: fullname: Bachtiary B – ident: e_1_2_8_31_1 doi: 10.1111/bju.12263 – ident: e_1_2_8_14_1 doi: 10.1016/j.clineuro.2013.06.019 – ident: e_1_2_8_25_1 doi: 10.1016/j.lungcan.2010.08.005 – ident: e_1_2_8_16_1 doi: 10.1111/j.1750-3639.2003.tb00013.x – ident: e_1_2_8_5_1 doi: 10.1016/j.radonc.2011.08.041 – ident: e_1_2_8_26_1 doi: 10.1016/j.semcancer.2012.06.001 – volume: 59 start-page: 5830 year: 1999 ident: e_1_2_8_27_1 article-title: Overexpression of hypoxia‐inducible factor 1alpha in common human cancers and their metastases publication-title: Cancer Res contributor: fullname: Zhong H – ident: e_1_2_8_33_1 doi: 10.1158/1078-0432.CCR-04-1776 – ident: e_1_2_8_28_1 doi: 10.1158/1078-0432.CCR-09-2439 – ident: e_1_2_8_22_1 doi: 10.1002/jcb.22214 – ident: e_1_2_8_8_1 doi: 10.1371/journal.pone.0092311 – ident: e_1_2_8_30_1 doi: 10.1093/annonc/mdp411 – ident: e_1_2_8_2_1 doi: 10.1016/j.ejca.2010.11.033 – ident: e_1_2_8_29_1 doi: 10.3171/2012.2.JNS111353 – ident: e_1_2_8_38_1 – ident: e_1_2_8_42_1 doi: 10.1093/neuonc/not112 – ident: e_1_2_8_20_1 doi: 10.1016/j.ejca.2012.07.002 – ident: e_1_2_8_3_1 doi: 10.1007/s11060-009-0061-8 – ident: e_1_2_8_24_1 doi: 10.1016/j.lungcan.2005.03.036 – ident: e_1_2_8_11_1 doi: 10.1007/s11060-009-9938-9 – ident: e_1_2_8_35_1 doi: 10.1038/bjc.2014.71 – ident: e_1_2_8_9_1 doi: 10.1371/journal.pone.0005857 – ident: e_1_2_8_34_1 doi: 10.1038/labinvest.2011.153 – ident: e_1_2_8_39_1 doi: 10.1586/14737140.2013.852067 – ident: e_1_2_8_12_1 doi: 10.5414/NP300600 – ident: e_1_2_8_6_1 doi: 10.1111/j.1468-1331.2006.01506.x – ident: e_1_2_8_10_1 doi: 10.1038/nm.2072 – ident: e_1_2_8_36_1 doi: 10.3171/2013.9.JNS13788 – ident: e_1_2_8_17_1 doi: 10.1111/j.1365-2559.2008.03065.x |
SSID | ssj0005769 |
Score | 2.3499525 |
Snippet | Aim
We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series.... We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series. Ki67... Aim We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis ( BM ) series.... Aim We aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM) series.... AIMWe aimed to characterize angiogenesis and proliferation and their correlation with clinical characteristics in a large brain metastasis (BM)... |
SourceID | proquest crossref pubmed wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | e41 |
SubjectTerms | Adult Aged Aged, 80 and over Angiogenesis brain metastases Brain Neoplasms - blood supply Brain Neoplasms - mortality Brain Neoplasms - secondary Breast cancer Breast Neoplasms - mortality Breast Neoplasms - pathology Carcinoma, Renal Cell - mortality Carcinoma, Renal Cell - pathology Cell Proliferation Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Female HIF-1 alpha index Humans Hypoxia-Inducible Factor 1, alpha Subunit - analysis Hypoxia-Inducible Factor 1, alpha Subunit - biosynthesis Immunohistochemistry Kaplan-Meier Estimate Ki-67 Antigen - analysis ki67 proliferation index Lung cancer Lung Neoplasms - mortality Lung Neoplasms - pathology Male Melanoma Melanoma - mortality Melanoma - pathology microvascular density Middle Aged Neovascularization, Pathologic - mortality Neovascularization, Pathologic - pathology Proportional Hazards Models |
Title | Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases |
URI | https://api.istex.fr/ark:/67375/WNG-PXDC1ZPB-R/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fnan.12185 https://www.ncbi.nlm.nih.gov/pubmed/25256708 https://www.proquest.com/docview/1648870019/abstract/ https://search.proquest.com/docview/1652424399 |
Volume | 41 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9VAEB5KBfFF67XpRVYR8SUlJ9lssvapttYi9FCKxYMIy17LoTYpPTkg_gX_tDO5aUVBfEpCdjebzczst9mZbwBepFLzxEx4LPAQE4VWLEuXxFoGl3EruW3juI-n4uiMv5_lsxXYHWJhOn6I8YcbaUZrr0nBtVn8ouSVrogaoaQAcyLSI0B0-pM6CnG07HYQ8hhXMaJnFSIvnrHmjbnoFg3r1z8BzZu4tZ14Du_B56HLnb_Jxc6yMTv2229sjv_5TmtwtwekbK-ToPuw4qsHcPu433J_CN8P-hQqaAq-MHJGZHVgujqf1-dkJ-cLvHCsWV5iS4z2AdgVZQIKvpMtNq-YoTwU7NI3GrHowmMNS4tenDVZU2PxlvBiaIJ-Cr_GNjuyFHoYwhtmqd4jODt8-2H_KO4zOMSWiOdjj3DUC-Glz2RiQoFWXiSlkzJkDpGY96URLmiXJjnagiAoPVnJg8l1EQonXfYYVqu68uvAAueZL6zQpTTcWq5top1MczMxKUWORfB8-Jaq77caFjg4rKod1ghetl95LKGvL8izrcjVx-k7dTI72J98OnmjTiPYGsRA9Uq9ULiyRJNMoDiCZ-NtVEcaW135ekllcgq4QdgXwZNOfMaHpTniyyIpI3jVCsHf-6mme9P2ZOPfi27CHQRzeedRvgWrzfXSbyNgaszTVjN-AIksEe4 |
link.rule.ids | 315,786,790,1382,27957,27958,46329,46753 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ta9RAEB5qC-oX37XRqquI-CUll-wmWfFLba2n9kIpLR6ChM2-lKNtIr0ciH_BP-3MJjmtKIifLkd2N5vNzOwzu7PPADyLpeJRNeJhij8hUWiFMjdRqKQzCdeSa3-Oe1Kk4yP-fiqmK_BqOAvT8UMsF9xIM7y9JgWnBelftLxWNXEj5OISrKG6C-9QHfwkj0IkLbs9BBGiH5P2vEIUx7OsemE2WqOB_fonqHkRufqpZ_c6fB463UWcnGwu2mpTf_uNz_F_3-oGXOsxKdvqhOgmrNj6Flye9Lvut-H7Tp9FBa3BKaN4RNY4purjWXNMpnI2xz-GtYszbInRVgD7QsmAnO3Ei81qVlEqCnZmW4VwdG6xhia_FydO1jZY3HNeDE3QuvBLbLPjS6GHIcJhmurdgaPdN4fb47BP4hBq4p4PLSJSm6ZW2kRGlcvQ0KdRbqR0iUEwZm1epcYpE0cCzYFLKUNZzl0lVOYyI01yF1brprbrwBznic10qnJZca250pEyMhbVqIrp8FgAT4ePWfb9LgcfB4e19MMawHP_mZcl1PkJBbdlovxYvC33pzvbo0_7r8uDADYGOSh7vZ6X6FyiVSZcHMCT5W3USBpbVdtmQWUEnblB5BfAvU5-lg-LBULMLMoDeOGl4O_9LIutwl_c__eij-HK-HCyV-69Kz48gKuI7UQXYL4Bq-35wj5E_NRWj7ya_ACldBYQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwEB6VVqp44T4CBQxCiJdU2cRxYngqXZZyNFpVVKwqJMvxUa1Ks1U3KyH-An-amVxQBBLiKYniK87M-LM9_gbgaSw1j8oRDwVeQqLQCmVuo1BLbxNuJDfNOe79Quwd8nezdLYGL_uzMC0_xLDgRprR2GtS8DPrf1HySldEjZCnl2CDiyQmkR4f_OSOQiAt2y2ENMRpjOhohciNZ8h6YTDaoH79-iekeRG4NiPP5Cp87tvcOpycbK_qctt8-43O8T8_6hpc6RAp22lF6DqsueoGbO53e-434fu4i6GCtuALI29EtvBMV8fzxTEZyvkSHyyrV6dYEqONAHZGoYC8a4WLzStWUiAKdupqjWB06TCHoVkvDpusXmDyhvGiL4JWhV9gmS1bClWG-IYZyncLDievP-7uhV0Ih9AQ83zoEI86IZx0iYxKn6GZF1FupfSJRSjmXF4K67WNoxSNgRcUnyznvkx15jMrbXIb1qtF5e4C85wnLjNC57LkxnBtIm1lnJajMqajYwE86f-l6tqt-hkOdqtqujWAZ81fHlLo8xNybctS9al4o6az8e7oaPpKHQSw1YuB6rR6qXBqiTaZUHEAj4fXqI_Ut7pyixWlSenEDeK-AO604jNUFqcIMLMoD-B5IwR_b6cqdorm5t6_J30Em9PxRH14W7y_D5cR2KWtd_kWrNfnK_cAwVNdPmyU5AdawxS_ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Differential+role+of+angiogenesis+and+tumour+cell+proliferation+in+brain+metastases+according+to+primary+tumour+type%3A+analysis+of+639+cases&rft.jtitle=Neuropathology+and+applied+neurobiology&rft.au=Berghoff%2C+Anna+S.&rft.au=Ilhan%E2%80%90Mutlu%2C+Ayseg%C3%BCl&rft.au=Dinhof%2C+Carina&rft.au=Magerle%2C+Manuel&rft.date=2015-02-01&rft.issn=0305-1846&rft.eissn=1365-2990&rft.volume=41&rft.issue=2&rft_id=info:doi/10.1111%2Fnan.12185&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_nan_12185 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-1846&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-1846&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-1846&client=summon |